Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis

Tsuchiya, Haruka; Fujio, Keishi

doi:10.3390/ijms22179534

Cited by 8 publications

(3 citation statements)

References 73 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It remains difficult to predict which drug will be effective for a given patient. 24 To overcome the challenges of current, ‘lottery-like’ 25 therapeutic approaches, there is a need for novel biomarkers tailored to patients’ expected therapeutic responsiveness. Synovial tissue research, for example, has become widely developed, but large discrepancies exist in the way synovial tissue is handled, and how data pertaining to biopsy procedure, quality check and experimental results are reported in the literature.…”

Section: Emerging Eular Research Centrementioning

confidence: 99%

Levelling the playing field of RMD research across Europe to address patients’ needs: the emerging EULAR Research Centre

et al. 2022

View full text Add to dashboard Cite

Herein, we describe the Research Centre launched by the European Alliance of Associations for Rheumatology (EULAR) in 2020. The Centre aims to facilitate collaborative research on rheumatic and musculoskeletal diseases (RMD) across Europe. RMDs disable millions of people in Europe and worldwide. Despite progress with improved therapeutics and strategic interventions in several RMDs, there are no cures, and their collective impact remains substantial. Access to RMD-related care, policies prioritizing RMDs, and related research, education, training, and funding differ significantly across European countries. Building a new equipoise in opportunity and capacity across Europe will facilitate optimal understanding of those different factors that influence the epidemiology, pathogenesis, treatment, and outcomes in RMDs. The EULAR Research Centre aims to address the significant barriers to accelerating RMD research across Europe. It provides an RMD research roadmap of unmet needs, expert services, infrastructures, networks, research resources, training, education, and mentoring. It will place RMD research in the ideal position to benefit from forthcoming remarkable advances in digital, biological, and social science anticipated in the coming decades.

show abstract

Section: Emerging Eular Research Centrementioning

confidence: 99%

Levelling the playing field of RMD research across Europe to address patients’ needs: the emerging EULAR Research Centre

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Proteomics is a valuable research for identifying functional molecules directly involved in the pathophysiology of RA. Serum protein analysis has been widely adopted in clinical practice for its less invasive nature and easy reproducibility compared with synovial sampling [ 2 ]. Mass spectrometry (MS) and immunoassays are two conventional methodologies for serum protein analysis.…”

Section: Introductionmentioning

confidence: 99%

Tailored therapeutic decision of rheumatoid arthritis using proteomic strategies: how to start and when to stop?

et al. 2023

View full text Add to dashboard Cite

Unpredictable treatment responses have been an obstacle for the successful management of rheumatoid arthritis. Although numerous serum proteins have been proposed, there is a lack of integrative survey to compare their relevance in predicting treatment outcomes in rheumatoid arthritis. Also, little is known about their applications in various treatment stages, such as dose modification, drug switching or withdrawal. Here we present an in-depth exploration of the potential usefulness of serum proteins in clinical decision-making and unveil the spectrum of immunopathology underlying responders to different drugs. Patients with robust autoimmunity and inflammation are more responsive to biological treatments and prone to relapse during treatment de-escalation. Moreover, the concentration changes of serum proteins at the beginning of the treatments possibly assist early recognition of treatment responders. With a better understanding of the relationship between the serum proteome and treatment responses, personalized medicine in rheumatoid arthritis will be more achievable in the near future.

show abstract

“…Поскольку периферическая кровь является самым доступным биоматериалом, а экспрессия генов -самой ранней клеточной реакцией организма на изменения окружающей среды [9], анализ экспрессии генов мононуклеарных клеток периферической крови (МКПК) может быть использован для оценки реакции пациента на терапию. Данные нашего ранее опубликованного исследования показали, что дости-жение клинической ремиссии у пациентов с РА, получавших TОФА, было связано с более низкой исходной экспрессией генов, участвующих в продукции энергии (пируваткиназы и сукцинатдегидрогеназы), по сравнению с остальными больными, в то время как отсутствие ответа на TОФА сопровождалось высокой базальной экспрессией этих генов [10].…”

unclassified

Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis

Маркова¹,

Tchetina²,

Сатыбалдыев³

2022

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

The effectiveness of personalized therapy for rheumatoid arthritis (RA) is associated with the correct choice of the drug and the ability to predict its effect before starting the treatment.Objective: to study in patients with RA the relationship between results of therapy and initial expression of genes responsible for bone and articular cartilage resorption (matrix metalloproteinase 9 – MMP9, – cathepsin K) and inflammation (tumor necrosis factor α – TNFα – and interleukin 1β – IL1β) in mononuclear cells of peripheral blood (PBMC), cultured with tofacitinib (TOFA).Patients and methods. We examined 12 patients with RA who had not previously received TOFA. The average age of the patients was 51 years, the average duration of the disease was 37.6 months. After 3 months of TOFA therapy, 6 patients achieved remission, while the rest had high and moderate disease activity. PBMC were isolated before therapy using a Ficoll density gradient and cultured in the presence of 100 nM TOFA for 48 h. Total RNA obtained from these cells was used to analyze the expression of MMP9, cathepsin K, IL1β, and TNFα genes using a real-time quantitative reverse transcription polymerase chain reaction.Results and discussion. TOFA is able to modify gene expression in cultured PBMC from RA patients compared to control cells. The initial expression of all the studied genes was significantly increased in cultured with TOFA cells of patients with persistent high and moderate disease activity during therapy, while TNFα gene expression was significantly reduced in patients who achieved remission.Conclusion. In patients with RA who have not previously received TOFA, a decrease in TNFα gene expression in blood cells cultured with this drug before the start of therapy may be a prognostic biomarker for achieving remission during TOFA therapy.

show abstract

Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis

Cited by 8 publications

References 73 publications

Levelling the playing field of RMD research across Europe to address patients’ needs: the emerging EULAR Research Centre

Levelling the playing field of RMD research across Europe to address patients’ needs: the emerging EULAR Research Centre

Tailored therapeutic decision of rheumatoid arthritis using proteomic strategies: how to start and when to stop?

Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis

Contact Info

Product

Resources

About